This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.
Market Introduction
The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.
Market Segmentation
Segmentation 1: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
How can this report add value to an organization?
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
- ALCEN
- bioMérieux S.A.
- CENTOGENE N.V.
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- QIAGEN N.V.
This product will be delivered within 3-5 business days.
Table of Contents
Companies Mentioned
- ALCEN
- bioMérieux S.A.
- CENTOGENE N.V.
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- QIAGEN N.V
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 70 |
| Published | July 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 7.19 Billion |
| Forecasted Market Value ( USD | $ 14.84 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 6 |
